BioMedNewsBreaks

TuesdayMay 16, 2023 1:23 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Featured in InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company has been awarded approximately C$2.81 million in an arbitration settlement. An InvestmentPitch Media video provides additional information about this news and the company. The video is available for viewing on InvestmentPitch and YouTube. To view the full press release, visit https://ibn.fm/2G1zT About FSD Pharma Inc. FSD Pharma is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences, a wholly owned…

Continue Reading

TuesdayMay 16, 2023 12:58 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q1 2023 Financial Results, Business Update

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting its financial results for the first quarter ended March 31, 2023; the report also noted key business updates. Highlights of the report indicate R&D expenses for quarter totaled $2 million with marketing, general and administrative expenses for the quarter reaching $1.2 million and total operating expenses coming in at $3.2 million, compared with $2.6 for same period in 2022. The report noted financial (loss) income for the quarter totaling $(0.3) million compared with $0.14 million for…

Continue Reading

MondayMay 15, 2023 3:31 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Q3 2023 Financial Results, Provides Business Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced financial results for the third quarter of the fiscal year 2023, which ended March 31, 2023. “The third quarter of fiscal year 2023 was an important period for InMed, as we achieved several key milestones across our different business segments, including completing enrollment in our phase 2 clinical trial for epidermolysis bullosa, marking the first time cannabinol (‘CBN’) has completed a phase 2 clinical trial. We look forward to the data read out during 3Q and will then…

Continue Reading

MondayMay 15, 2023 2:38 pm

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Reports on Q1 2023 Financial Results

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair metabolism and skin therapies, has release a report on its first-quarter revenues for the period ended March 31, 2023. The company reported revenues for the quarter totaled $1,121,676, compared to $721,629 in Q1 2022. Operating expenses for the quarter came in at $1,496,537, compared to $2,978,933 for the same period in 2022, and net losses totaled $1,308,174 for the three months, compared to $2,919,775 for the same period in 2022. “I am thrilled with our team's progress this quarter, demonstrating substantial revenue growth and a significant reduction in operating expenses,”…

Continue Reading

MondayMay 15, 2023 2:25 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q1 2023 Results, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced its financial results for the quarter ended March 31, 2023. In addition, the company provided a clinical update of its anti-cancer drug candidate currently in development for the treatment of primary and metastatic brain and CNS cancer. “Over the course of the first quarter, our team has continued its flawless operational execution of our potentially pivotal study witnessed by our recent enrollment update boasting 100 patients now dosed in this global clinical…

Continue Reading

MondayMay 15, 2023 1:31 pm

BioMedNewsBreaks – Progressive Care Inc. (RXMD) Releases Record breaking Q1 2023 Financial Results

Progressive Care (OTCQB: RXMD), a personalized healthcare services and technology provider, is reporting its financial results for the first quarter ended March 31, 2023. According to the report, the company saw record quarterly revenue; the report showed a $11.4 million revenue for the first quarter, a 13% increase from the first quarter ended March 31, 2022. Other highlights include total pharmacy revenue increasing by $1.3 million, or 13%; prescription revenue increased by $1.8 million, or 21%, to total $10.4 million during the first quarter of 2023; 340B contract revenue for the quarter was $1.6 million, an increase of $1.2 million; gross…

Continue Reading

MondayMay 15, 2023 1:09 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Reports Filing of Complaint, Update on Spin-Out Transaction

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, is reporting that a complaint against the company and its subsidiary, FSD Biosciences Inc., was filed on May 1, 2023. The complaint was filed in the United States District Court for the Southern District of Florida by GBB Drink Lab Inc. FSD Pharma received a copy of the complaint on May 9, 2023. According to the announcement, the complaint states that “FSD breached a mutual nondisclosure agreement and…

Continue Reading

FridayMay 12, 2023 12:14 pm

BioMedNewsBreaks – Progressive Care Inc. (RXMD) Secures Additional $1M Investment From NextPlat Corp. (NASDAQ: NXPL)

Progressive Care (OTCQB: RXMD), a personalized healthcare services and technology provider, has announced its successful completion of a transaction of $1 million investment from NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider. In connection with the $1 million investment, the company sold to NextPlat 455,000 newly issued units, with each comprised of one share of the company’s common stock and one warrant to purchase a share of common stock and a per-unit purchase price of $2.20. In addition, Charles M. Fernandez, who serves as chairman and CEO of both Progressive Care and NextPlat, Rodney Barreto, vice chairman of Progressive Care…

Continue Reading

FridayMay 12, 2023 11:26 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q1 2023 Financial Report, Corporate Updates

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram ("VECG") platform for heart attack detection anytime, anywhere, is reporting its operational and financial results for the first quarter 2023, the period ended March 31, 2022. Key takeaways from the report include that the company closed on a $26.5million with a public offering and registered direct offering, raising funds that BEAT anticipates using to execute on upcoming clinical, regulatory and commercial milestones as well as extend cash runway into late 2024. In addition, the report noted that HeartBeam has adjusted its strategic focus to…

Continue Reading

ThursdayMay 11, 2023 2:29 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Secures $2.81M in Cost Awards from Dr. Raza Bokhari

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced that in a cost award decision dated May 6, 2023, the Honorable J. Douglas Cunningham, K.C. (“Justice Cunningham”) ruled in favor of FSD Pharma, awarding the company approximately $2.81 million all in Canadian dollars costs of arbitration in the arbitration between FSD Pharma and its former CEO Dr. Raza Bokhari. In July 2021, the board of directors for FSD Pharma unanimously voted to…

Continue Reading